ClinicalTrials.gg
CompletedNCT06738719Updated Apr 23, 2026

A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Phase 3 interventional study of CT-P13 SC Auto-Injector and Placebo Auto-Injector in Moderately to Severely Active Rheumatoid Arthritis, sponsored by Celltrion. Completed at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Celltrion · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies in Arthritis, Rheumatoid by Celltrion — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Celltrion.

Enrollment
8th of 12
192 · median 286
Started
2025
the only one that year
Phase 3
10 of 15
none open now
Registered
15th of 15
by date

Among the 15 studies in Arthritis, Rheumatoid by Celltrion, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 10 in phase 3, and was the 15th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 15 studies in Arthritis, Rheumatoid by Celltrion is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Arthritis, Rheumatoid by Celltrion as a file.
02

Study summary

This is a Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis

03

Conditions studied

  • Moderately to Severely Active Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

[Main Inclusion Criteria]

  1. Patient who is male or female aged 18 to 75 years old (both inclusive).
  2. Patient who has a diagnosis of RA at least 24 weeks prior to the first administration of the study drug (Day 1) and fulfill the 2010 ACR/EULAR classification criteria for RA.
  3. Patient who has active disease as defined by the presence of 6 or more swollen joints (of 66 assessed), 6 or more tender joints (of 68 assessed), and either a high-sensitivity C-reactive protein (hsCRP) ≥1.0 mg/dL (≥10 mg/L) or an erythrocyte sedimentation rate (ESR) ≥28 mm/hour at Screening.
  4. Patient who has been receiving the treatment of oral or parenteral dosing with MTX for at least 12 weeks and has been on stable dosing with MTX between 10 to 25 mg/week for at least 4 weeks prior to the first administration of the study drug (Day 1).
  5. Patient who has adequate renal and hepatic function at Screening

[Main Exclusion Criteria]

  1. Patient who has previously received or licensed product; biological agents or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) (e.g., tofacitinib, baricitinib) for the treatment of RA and/or a tumor necrosis factor (TNF) α inhibitors for the any purpose.
  2. Patient who has allergies to any of the of infliximab or any other murine and/or human proteins or patient with a to immunoglobulin product.
  3. Patient who has received or has plan to receive any of prohibited medications or treatments as defined in the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    CT-P13 Auto-Injector

    CT-P13 SC(Subcutaneous) Auto-Injector

    Biological: CT-P13 SC Auto-Injector

  • Placebo comparator
    Placebo Auto-Injector

    Placebo Auto-Injector

    Biological: Placebo Auto-Injector

Interventions

  • BiologicalCT-P13 SC Auto-Injector

    Subcutaneous(SC) Injection

  • BiologicalPlacebo Auto-Injector

    Subcutaneous(SC) Injection

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving clinical response according to the ACR20 criteria at Week 12

    To demonstrate superiority of CT P13 SC over Placebo in terms of efficacy as determined by clinical response according to the American College of Rheumatology (ACR) definition of a 20% improvement (ACR20) at Week 12

    Time frame: Week 0 ~ Week 12

Secondary outcomes

  1. Change from baseline in HAQ-DI at Week 12

    Difference in mean change from baseline in HAQ-DI between treatment groups (CT-P13 SC and Placebo)

    Time frame: Week 0 ~ Week 12

  2. Evaluate Pharmacokinetics of CT-P13 SC

    Serum concentration of infliximab

    Time frame: Up to 52 Weeks

  3. Evaluate Safety of CT-P13 SC

    * Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 * All reported terms of AEs will be coded to system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) and severity grading of AEs will be recorded according to the CTCAE Version 5.0

    Time frame: Up to 52 Weeks

07

Study locations

1 site
  • Klinika Reuma Park Sp. z.o.o
    Warsaw, 02-665, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jun 2025, 5 months.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 5 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 18, 2024
StartActual
Jan 3, 2025
Primary completionActual
Jun 25, 2025
CompletionActual
Apr 13, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06738719
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Jan 3, 2025
Primary completion
Jun 25, 2025
Completion
Apr 13, 2026
Last update
Apr 23, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion